載入中
NASDAQHealthcareBiotechnology
最新資料
US$10.52
+US$0.31 · +3.04%
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
前收盤價
US$10.52
+US$0.31 · +3.04%
盤中時間採用ET。市場資料可能有所延遲。
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
日內區間
目前US$10.52
52週區間
目前US$10.52
盤中時間採用ET。市場資料可能有所延遲。
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
日內區間
目前US$10.52
52週區間
目前US$10.52
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 10.5萬 USD | — | — | — | — |
| 毛利 | −10.5萬 USD | — | — | — | — |
| 研究與開發 | 3371.9萬 USD | 1938.5萬 USD | 1652.6萬 USD | 2446.8萬 USD | 2911.5萬 USD |
| 銷售、一般及管理費用 | 925.2萬 USD | 816.3萬 USD | 688.1萬 USD | 809.7萬 USD | 951.5萬 USD |
| 營業費用 | 4286.6萬 USD | 2754.8萬 USD | 2340.7萬 USD | 3256.5萬 USD | 3863萬 USD |
| 利息收入 | 250.5萬 USD | 182.4萬 USD | 158.4萬 USD | 65.4萬 USD | — |
| 利息支出 | — | — | — | — | 1.5萬 USD |
| 折舊和攤銷 | 10.5萬 USD | 8.5萬 USD | 15.1萬 USD | 36.7萬 USD | 46萬 USD |
| 營業利益 | −4297.1萬 USD | −2754.8萬 USD | −2340.7萬 USD | −3256.5萬 USD | −3863萬 USD |
| 淨利 | −1528.3萬 USD | −6229.3萬 USD | −2702.9萬 USD | −4130.7萬 USD | −4324.1萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$40.00
上漲空間 280.23%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3379.53萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1874.67萬0.19%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1721.77萬0.02%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1209.4萬0.01%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO602.16萬0.04%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO546.14萬0.03%180億 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB506.46萬0.05%108.2億 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA405.37萬0.02%218.24億 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
